Pathogenesis (Chronic follicular inflammatory disease — not a classical infection; skin flora (Staphylococcus lugdunensis, Cutibacterium spp.) and anaerobes in biofilms may trigger inflammation (European S2k, NA HS Guidelines))
Clinical context (Hurley stage I (single/multiple abscesses without sinus tracts) or mild stage II — topical antibiotics first-line for limited inflammatory lesions (NA HS Part II, European S1/S2k))
First-line therapy
Clindamycin • topical
Duration: 12 weeks · Clindamycin 1% solution or gel (10 mg/mL) applied BID × 12 weeks — RCT evidence in Hurley I–II; pediatric extrapolation × 3 months (NA HS Part II, Mikkelsen & Jemec 2014)
• Antibiotics treat inflammation and flares — HS is a chronic follicular disease; antibiotics are not curative monotherapy and must be combined with hygiene, weight management, and specialist follow-up (European S2k, NA pediatric HS 2024).
• Topical clindamycin: Hurley stage I or mild stage II with limited superficial pustules/papules — reduces pustules in RCTs; limited effect on deep nodules/abscesses (NA HS Part II, Clemmensen 1983 RCT).
• Use concomitant antiseptic washes (e.g. chlorhexidine, benzoyl peroxide) with topical antibiotics to reduce bacterial resistance — NA pediatric HS guideline 2024 (statement 45).
• Escalate to systemic therapy if inadequate response at 12 weeks, Hurley stage II–III progression, or widespread inflammatory disease (European S2k, NA HS algorithm).
• Routine wound culture not recommended for typical HS lesions without fever — microbiology is probabilistic; culture only if superinfection or systemic illness suspected (European/French HS antibiotherapy guidance).
Topical adjuncts or short systemic course • topical / p.o.
Duration: 12 weeks · Select when topical clindamycin insufficient or intolerance — dermatology referral recommended
• Topical resorcinol or retinoids: select pediatric cases per NA pediatric HS 2024 — specialist-guided; resorcinol limited pediatric data (statements 48–49).
• Oral doxycycline: escalate to moderate-disease variant when age ≥8 years and topical therapy fails — not first-line for mild localized disease (NA pediatric HS 2024).
• Weight loss, smoking cessation (adolescents), gentle antiseptic skin care, loose clothing, and pain control are foundational — antibiotics adjunctive only (European S2k, NA HS Part I).
• Incision and drainage: acute painful fluctuant abscess only — not routine for all nodules; insufficient as sole long-term strategy (NA HS Part II).
• Superinfection: treat acute bacterial superinfection of lesions separately with culture-directed antibiotics if systemic signs — distinct from chronic HS anti-inflammatory antibiotic use (Mikkelsen & Jemec).
Clinical notes
• Hurley staging: stage I — abscesses without sinus tracts/scars; stage II — recurrent abscesses with tract formation and scars; stage III — diffuse involvement with multiple interconnected tracts (Hurley; maps to IHS4 mild/moderate/severe for medical therapy).
• Topical vs systemic: topical clindamycin 1% BID for Hurley I/mild II limited disease; systemic antibiotics for moderate inflammatory Hurley II, widespread lesions, or topical failure (NA HS Part II, European S2k 2024).
• I&D indications: acute symptomatic fluctuant abscess causing severe pain — temporary relief; chronic disease requires medical/surgical disease-modifying therapy, not repeated I&D alone (NA HS guidelines).
• Surgical management: deroofing, laser, or wide local excision for Hurley II–III chronic sinus tracts and scarring — predominantly non-inflammatory or structurally damaged tissue; coordinate with pediatric surgery/dermatology (European S2k).
• Recurrence prevention: weight optimization, antiseptic washes, smoking avoidance, topical maintenance, and early escalation before scarring — recurrence common without multimodal therapy; biologics not first-line for Hurley I (NA pediatric HS 2024, European S2k).
• NA HS Foundations — Medical management guidelines Part II (2019)
• NA Clinical Practice Guidelines — HS in special populations (pediatrics) (2024)
• European S2k guideline — HS/acne inversa treatment (update of S1) (2024)
+ 4 more
• Mikkelsen & Jemec — HS in children and adolescents treatment review (2014)
• AAP Red Book — Tetracyclines and skin infections (principles) (2024)
